Diabetes

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

By

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

By

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

Five things for pharma marketers to know: Monday, April 13

Five things for pharma marketers to know: Monday, April 13

By

Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests

Five things for pharma marketers to know: Friday, April 10

Five things for pharma marketers to know: Friday, April 10

By

AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce

FDA Onglyza panel review set for Tuesday

FDA Onglyza panel review set for Tuesday

By

The panel will focus on heart failure hospitalization rates associated with the diabetes medication.

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

By

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Five things for pharma marketers to know: Friday, March 27

Five things for pharma marketers to know: Friday, March 27

By

Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

By

Oncology and diabetes medications are expected to be major areas of growth.

Medtronic teams up with Glooko

The diabetes device manufacturer will soon work with Glooko's platform.

Five things for pharma marketers to know: Thursday, March 12

Five things for pharma marketers to know: Thursday, March 12

By

The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.

AstraZeneca, Joslin Diabetes Center ink three-year collaboration

The partners will focus on developing treatments for metabolic disorders.

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

By

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Sanofi's new Lantus may not be the new Lantus

Sanofi's new Lantus may not be the new Lantus

By

Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.

Lilly Lantus biosimilar to hit EU

The EU will have access to the new medication in May.

Lilly peglispro delay may be boon for its biosimilar

Lilly peglispro delay may be boon for its biosimilar

By

The drugmaker wants to put the drug through additional liver-impact tests.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

By

An NIH study shows possible limit to Lucentis's appeal.

Merck Januvia survey sparks ethics debate

A Merck survey that indicated distaste for British Columbia's decision to boot Januvia from the formulary has stirred up debate over bias.

Five things for pharma marketers to know: Monday, February 9

Five things for pharma marketers to know: Monday, February 9

By

Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.

CDC: diabetes patient costs have doubled

The reason: higher prices and more services.

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

By

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Five things for pharma marketers to know: Wednesday, January 28

Five things for pharma marketers to know: Wednesday, January 28

By By

Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.

Five things for pharma marketers to  know: Thursday, January 8

Five things for pharma marketers to know: Thursday, January 8

By By By

Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.

Novo seeks to make Saxenda a familiar name in weight loss

Novo seeks to make Saxenda a familiar name in weight loss

By

The company is set to introduce its newest brand, Saxenda, into the crowded prescription obesity market as a higher-dose form of liraglutide than diabetes shot Victoza.

Five things for pharma marketers to know: Monday, December 29

Five things for pharma marketers to know: Monday, December 29

By

FDA clears Novo's liraglutide for obesity; doctors' views vary on Express Scripts' hep.-C plan; Janssen, Gilead advance plans for HIV drugs.

Sanofi offers glimpse of next-gen. insulin strategy

Sanofi offers glimpse of next-gen. insulin strategy

By

In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.

Obesity drug war may be about more than marketing to the overweight

Obesity drug war may be about more than marketing to the overweight

By

Category news shows that marketing to the obese may mean marketing to related conditions.

Five things for pharma marketers to know: Wednesday, November 5

Five things for pharma marketers to know: Wednesday, November 5

By By

The Hill outlines its healthcare expectations with a GOP Congress, Sanofi's executive shakeup may have an impact on MannKind's Afrezza launch, AstraZeneca's olaparib may have prostate cancer prospects, the FDA granted orphan status to an experimental Merrimack pancreatic cancer drug, and researchers are struggling to get Ebola virus samples.

Lilly sales fall, drugmaker to keep rep count low

Lilly sales fall, drugmaker to keep rep count low

By

Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.

Task Force endorses T2D screening

The US Preventive Services Task Force wants adults at risk for type 2 diabetes to get tested.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters